Drug intelligence / Profile preview

APSCTC

Development stage: Phase 3
Lead developer: Apsen Farmacêutica

Overview

APSCTC is a drug developed by Apsen Farmaceutica S.A. It is currently undergoing a National, Multicentre, Randomized, Double-blind, Triple-dummy Active-Controlled Phase III Clinical Trial to evaluate its efficacy and safety for the treatment of postsurgical pain, specifically pain resulting from third molar extraction. The study aims to assess APSCTC's effectiveness in acute pain relief compared to two active comparator drugs.

Beyond the preview

Go deeper on APSCTC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APSCTC.

Explore the full profile